SEC Won't Comment on Speculation of Valeant Pharmaceuticals (VRX) Probe
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Valeant Pharma (VRX) Used Backdoor Approach to Gain Pharmacy Stake in California - ProPublica
October 22, 2015 5:48 PM EDTValeant Pharma (NYSE: VRX) is on watch following a new article from ProPublica which highlights documents that raise new questions about the company's pharmacy relationships in California.
From the... More
